Systems Pharmacology

We undertake Systems Pharmacology approaches to personalize multi-agent anticancer pharamcotherapies integrating individual patient data into treatment decision. Such mathematical models are designed though a multi-scale pipeline integrating experimental data from cell culture and animal experiments, together with clincial results from investigations in individual patients of cohorts of patients.

Personalizing Anticancer Drug Combinations

Cancer Research has led to the development of a new type of anticancer agents called "targeted molecules" which aim to specifically target a particular protein. They are generaly administered in combination with cytotoxic drugs which create DNA damage potentially leading to cell death. Our Research focuses on developping mathematical models ale to predict optimal drug combinations fro each individual patient. Those models are informed by multiple datasets measured in individual patients including tumor multi-omics information.

Personalizing Cancer Chronotherapeutics

Most physiological functions in mammals display rhythms of period around 24 h, also called circadian rhythms. This temporal organization of the organism results in variations in the toxicity and efficacy of many antidrugs with respect to their circadian time of administration. Recent experimental and clinical results support the need of personalizing the chronomodulated administration pattern according to the patient genetic and circadian profile. My Research works propose a systems biomedicine approach for the optimization of the circadian delivery of anticancer drugs, with particular focus on irinotecan (CPT11), a drug approved for the treatment of colorectal cancer.

Download PhD Thesis of Annabelle BALLESTA (Size=20Mb)